Inhibrx Biosciences CEO Mark Lappe reports acquisition of 10,040 common shares for $848,976.8365
Bitget2026/10/14 22:59- Inhibrx Biosciences CEO and director Mark Lappe purchased 10,040 common shares through two trusts.
- Reported purchase prices were $84.0707, $84.9992 and $85.76 per share.
- His indirect beneficial ownership totaled 970,453 common shares following the purchases.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
British Pound: Wider trading range expected against US Dollar – UOB
British Pound holds gains as UK GDP and Industrial Production beat expectations
UBS: Resumes coverage of Regeneron Pharmaceuticals (REGN.US) with a "Buy" rating; potential of blockbuster drug Dupixent underestimated
UBS has resumed coverage of Regeneron Pharmaceuticals (REGN.US) with a "Buy" rating and a target price of $978.
IMF sounds the alarm: Energy shocks and rising US Treasury yields pose spillover risks, Asia’s growth may slow to 4.4% next year
The IMF has lowered its growth forecast for Asia to 4.4% for next year, warning of three major risks: energy shocks, a correction in the AI boom, and rising global yields. The IMF also urged central banks to focus on price stability and avoid broad-based fuel subsidies.
Crypto prices
More
